Deverapalli SC - Search Results

1

Deverapalli SC, Jacob J, Santoro F. Deverapalli SC, et al. Cutis. 2017 Sep;100(3):E11-E13. Cutis. 2017. PMID: 29121132 No abstract available.

2

Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.

Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Kaye A, et al. Among authors: deverapalli sc. JAMA Dermatol. 2018 Oct 1;154(10):1225-1226. doi: 10.1001/jamadermatol.2018.2526. JAMA Dermatol. 2018. PMID: 30140849 No abstract available.

3

The use of antivirals in severe or recalcitrant cases of pityriasis rosea: A case series.

Tzur L, Yang FS, Deverapalli S. Tzur L, et al. JAAD Case Rep. 2022 Jun 9;28:100-103. doi: 10.1016/j.jdcr.2022.05.032. eCollection 2022 Oct. JAAD Case Rep. 2022. PMID: 36159717 Free PMC article. No abstract available.

4

Response to ustekinumab in three pediatric patients with alopecia areata.

Aleisa A, Lim Y, Gordon S, Her MJ, Zancanaro P, Abudu M, Deverapalli SC, Madani A, Rosmarin D. Aleisa A, et al. Among authors: deverapalli sc. Pediatr Dermatol. 2019 Jan;36(1):e44-e45. doi: 10.1111/pde.13699. Epub 2018 Oct 18. Pediatr Dermatol. 2019. PMID: 30338558

5

JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis.

Kahn JS, Deverapalli SC, Rosmarin DM. Kahn JS, et al. Among authors: deverapalli sc. Int J Dermatol. 2018 Aug;57(8):1007-1014. doi: 10.1111/ijd.14064. Epub 2018 Jun 5. Int J Dermatol. 2018. PMID: 29873082 Review.

6

The use of JAK inhibitors in the treatment of progressive systemic sclerosis.

Deverapalli SC, Rosmarin D. Deverapalli SC, et al. J Eur Acad Dermatol Venereol. 2018 Aug;32(8):e328. doi: 10.1111/jdv.14876. Epub 2018 Mar 6. J Eur Acad Dermatol Venereol. 2018. PMID: 29444362 No abstract available.

7

JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.

Kahn J, Deverapalli SC, Rosmarin D. Kahn J, et al. Among authors: deverapalli sc. Semin Cutan Med Surg. 2018 Sep;37(3):198-208. doi: 10.12788/j.sder.2018.041. Semin Cutan Med Surg. 2018. PMID: 30215638 Review.

8

Vitiligo adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021.

Learned C, Cohen SR, Alsukait S, Deverapalli S, Rosmarin D. Learned C, et al. J Am Acad Dermatol. 2023 Jan;88(1):197-199. doi: 10.1016/j.jaad.2022.04.010. Epub 2022 Apr 12. J Am Acad Dermatol. 2023. PMID: 35427685 No abstract available.

9

Importance of light in the treatment of vitiligo with JAK-inhibitors.

Joshipura D, Plotnikova N, Goldminz A, Deverapalli S, Turkowski Y, Gottlieb A, Rosmarin D. Joshipura D, et al. J Dermatolog Treat. 2018 Feb;29(1):98-99. doi: 10.1080/09546634.2017.1339013. Epub 2017 Jun 29. J Dermatolog Treat. 2018. PMID: 28581823 Free article. No abstract available.

10

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021.

Learned C, Alsukait S, Deverapalli S, Elliott E, Moody K, Sobell J, Konnikov N, Ortega M, Rosmarin D. Learned C, et al. JAAD Int. 2022 Apr 18;7:144-145. doi: 10.1016/j.jdin.2022.03.010. eCollection 2022 Jun. JAAD Int. 2022. PMID: 35497638 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters